Principal Investigator
Dr. Waldman’s career has focused on integrating basic, translational, and clinical research in transmembrane signaling to advance laboratory discovery into patients.
- This work has produced >300 publications (h index=68, >17,000 citations) and >100 patents and patent applications
- Discoveries have been licensed by 7 companies and have been the focus of >15 clinical trials
- Internationally recognized leader in the field of clinical pharmacology
- Editor-In-Chief of Clinical Pharmacology & Therapeutics, Founder and Editor of Biomarkers in Medicine, and Founder and former Deputy Editor-In-Chief of Clinical and Translational Science
- Retired Chair of NCI Subcommittee
- Recently (2019) retired chair of the FDA Pharmaceutical Science and Clinical Pharmacology Advisory Committee
- Recurring member of the FDA Oncology Drugs and the Arthritis Drugs Advisory Committee
- Past President of the American Society for Clinical Pharmacology and Therapeutics, a former Regent of the American College of Clinical Pharmacology, and the former Secretary/Treasurer of the American Board of Clinical Pharmacology
- Institutionally, Director of the KCC Gastrointestinal (GI) Malignancies Program, the MD-PhD Program, and the Postdoctoral Training Program in Clinical Pharmacology (5T32 GM08562)
- Chairman (tenured), Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA
- MD, Stanford University
- PhD, Thomas Jefferson University
